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Abstract We have developed an operationally simple, time 4 
and cost-effective protocol to produce a novel tetrazine-based 5 
iron oxide nanoparticle using commercially available and 6 
inexpensive materials. Our protocol proceeds at room 7 
temperature and uses Hexafluorophosphate Azabenzotriazole 8 
Tetramethyl Uronium, a well-known, widely used reagent for 9 
the large-scale industrial production of important 10 
pharmaceuticals. The nanoparticles obtained have a diameter 11 
range between 16 and 21 nm and showed no toxicity against 12 
endothelial cell lines. The tetrazine moiety on the 13 
nanoparticle surface could potentially allow further 14 
attachment of specific targeting vectors by using so-called 15 
copper-free click chemistry. We therefore anticipate that our 16 
protocol can represent a significant breakthrough in the future 17 
development and commercialization of improved, tissue-18 
specific contrast agents and drug delivery for clinical 19 
diagnosis, monitoring and therapy of diseases at an 20 
asymptomatic stage.  21 
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Introduction 27 
 28 
Since their discovery (Ohgushi, 1978), Iron Oxide 29 
Nanoparticles (IONPs) have emerged as powerful tools for a 30 
wide scope of applications such as in the fields of biolabeling, 31 
medical diagnostics, and therapy (Colombo et al. 2012). In 32 
particular as contrast agents for magnetic resonance imaging 33 
(MRI), IONPs have attracted enormous attention. IONPs 34 
have a transverse relaxivity which increases at higher 35 
magnetic fields, resulting in enhanced signal-to-noise ratio 36 
with lower dosages (Mishra et al. 2016). The use of IONPs 37 
for diagnostic imaging is therefore expected to increase 38 
steadily. Unlike Gd-based contrast agents (CAs), IONPs have 39 
proven safe with some systems already approved for clinical 40 
use (Schmitz et al. 2001; Trivedi et al. 2004). With the recent 41 
advent of molecular imaging (Meloni et al. 2017), IONPs are 42 
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increasingly used for the preparation of targeted CAs, 43 
allowing non-invasive visualization of biomolecules which 44 
are the signatures of diseases in specific body tissues, both in 45 
vivo and in real time. The preparation of these targeted CAs 46 
firstly involves coating of the IONPs surface with a 47 
biocompatible, clinically approved polymer, followed by its 48 
functionalization with a targeting vector which allows tissue 49 
specificity (A. M. Morawski et al. 2005). 50 
 51 
This process, so-called standard bioconjugation, uses well-52 
established synthetic chemistry and involves the formation of 53 
stable chemical bonds. Despite being reliable, this method 54 
can lead to low yields and produce toxic byproducts, resulting 55 
in expensive, time-consuming purifications and toxicological 56 
screenings. A number of years may therefore be required for 57 
the translation, large scale production and commercialization 58 
of targeted, nanoparticle-based CAs into the clinical market. 59 
 60 
Copper-free click reactions recently emerged as a powerful, 61 
time-saving bioconjugation strategy to prepare targeted CAs 62 
(Devaraj and Weissleder 2011; McKay and Finn 2014). 63 
Copper-free click reactions are operationally simpler and 64 
proceed at room temperature. They eliminate the use of 65 
cytotoxic copper catalysts (Baskin JM et al. 2007) and are 66 
inert to both water and oxygen. They also generate minimal, 67 
inoffensive byproducts, providing the best yield with the 68 
highest reaction rates. Copper-free click reactions can 69 
proceed in living organisms, allowing the targeting of 70 
biomolecules with high specificity without altering any native 71 
biochemical process. Among the arsenal of available copper-72 
free click reactions, the Inverse Electron Demand Diels Alder 73 
(IEDDA) reaction stands out as the most promising one for 74 
its rapid reaction rate and generation of safe, inert nitrogen as 75 
the only byproduct (Oliveira et al. 2017). IEDDA reactions 76 
also involve tetrazines and cycloalkenes, both of which are 77 
easier substrates to prepare if compared to 78 
azadibenzocyclooctynes (DIBACs) (Debets et al. 2010) and 79 
biarylazacyclooctynones (BARACs) (Kuzmin et al. 2010). 80 
Despite such significant advantages, the preparation of 81 
targeted, nanoparticle-based CAs using IEDDA is a relatively 82 
unexplored field. A possible reason is a shortage of reliable 83 
protocols to prepare tetrazine-based IONPs. Therefore, the 84 
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3 
identification of novel, green and efficient ways to prepare 1 
these functional nanoparticles can accelerate the development 2 
of improved contrast agents for diagnosis and therapy. In this 3 
paper we designed and synthesized a novel route to a 4 
tetrazine-bound nanoparticle 4 (Scheme 1). 5 
 6 
 7 
Scheme 1 (a) Oleic acid, oleylamine, phenyl ether (b) BTAC, 8 
KMnO4 (c). Tetrazine 5, HATU, DIPEA, CH2Cl2, at room 9 
temperature. 10 
 11 
As illustrated above, our strategy involved the loading of a 12 
tetrazine moiety to nanoparticles 3 using 13 
Hexafluorophosphate Azabenzotriazole Tetramethyl 14 
Uronium (HATU), a readily available, inexpensive and well-15 
known reagent. Our overall approach to nanoparticles 4 can 16 
be exploited for the future production of improved contrast 17 
reagents, with potential application also in the fields of 18 
nanomedicine. 19 
 20 
Results and discussion 21 
 22 
In this work, we successfully designed and developed an 23 
operationally simple, economical and productive approach to 24 
produce a novel tetrazine-decorated IONP 4 (Scheme 1, page 25 
2). Our protocol is reproducible by taking an advantage of 26 
well-established chemistry and usages of building blocks 3 27 
and 5, both accessible via established published protocols 28 
(Herranz et al. 2008; Evans et al. 2014). Nanoparticles 4 were 29 
obtained via coupling between carboxylic acid IONPs 3 and 30 
tetrazine-based amine 5 (Scheme 1, page 2). Our method 31 
builds upon the reaction between a carboxylic acid and an 32 
amine, which produces extremely stable chemical bonds even 33 
in a biological environment and is one of the most robust, 34 
known reactions in synthetic chemistry (Jaradat, 2018). 35 
During this process a challenge also emerged due to the 36 
presence of the paramagnetic core both in 3 and 4, which 37 
excluded quantitative reaction monitoring via NMR. 38 
Therefore, we first decided to validate the chemistry using 39 
acetic acid as a surrogate for nanoparticles 3. We wanted a 40 
fast, high yielding protocol to obtain model compound 6. 41 
After unsuccessful attempts to prepare this latter using N-42 
hydroxysuccinimide (NHS) and 1-Ethyl-3-(3-43 
dimethylaminopropyl)carbodiimide (EDC) in water (Herranz 44 
et al. 2008), we found that the system HATU/DIPEA/CH2Cl2 45 
afforded 6 in 92% yield after only 3 hours. 46 
We therefore adopted this method for the synthesis of 47 
nanoparticles 4. Coupling between 3 and 5 was performed 48 
with HATU and DIPEA in CH2Cl2, affording the desired 49 
nanoparticles 4. We found this method both safe and 50 
operationally simple for many reasons. Firstly, HATU is an 51 
established chemical which is widely used during large scale 52 
synthesis of pharmaceuticals. Several reports of HATU 53 
applications have showcased its use in the synthesis of 54 
promising drug candidates (Dunetz et al. 2016 and references 55 
cited herein). Secondly, a simple filtration/washing cycle can 56 
be used to purify and isolate nanoparticles 4. Thirdly, the 57 
reaction also proceeded both at room temperature and in 58 
presence of relatively safe chemicals. Finally, our approach is 59 
highly reproducible. As a proof, we repeated the synthesis 60 
three times, obtaining nanoparticles 4 with the same zeta 61 
potentials in all cases (see Table 1). Yields of nanoparticles 4 62 
were 91%, 88% and 90% for repetitions 1-3 respectively. We 63 
therefore believe that our approach to nanoparticles 4 can be 64 
feasible for a scale-up production. The tetrazine grafted on 65 
IONP render a nano-platform for conjugating a diverse range 66 
of biomolecules or drugs via copper-free click chemistry. 67 
This strategy has advantages of simplifying chemical 68 
synthesis, avoiding cytotoxic copper catalysts and generating 69 
a system to detect biomarkers in live cells with improved 70 
sensitivity. One such example is the nanoparticle-antibody 71 
conjugate developed to image extracellular receptors in 72 
cancer cells (Haun et al. 2010). 73 
 74 
Table 1. Zeta potentials found for nanoparticles precursor 3, 75 
tetrazine bound IONPs 4 and yields obtained. 76 
 77 
Sample 
(repeat) 
IONPs 3 
(mV) 
IONPs 4 
(mV) 
1 -37.6 -20.5 
2 -41.1 -16.1 
3 -42.9 -18.1 
 78 
With nanoparticles 4 successfully prepared, we then decided 79 
to assess their shape and average size. These parameters are 80 
relevant in assessing IONPs sensitivity for biosensing 81 
applications. As a proof, in 2013 Kolhatkar et al. 82 
demonstrated that cubic and spherical nanoparticles display 83 
different sensitivities due to their different contact areas. With 84 
this in mind, we obtained TEM images of IONPs 4 (Figures 85 
1a-d). It can be seen that the particles are spherical in shape 86 
with a size range between 16 and 21 nm. 87 
 88 
 89 
Figures 1a-d. TEM Images of nanoparticles 2 90 
 91 
Once that both shape and size of the nanoparticles were 92 
assessed, we moved to establish their magnetic properties. 93 
(1a) 
(1b) 
(1c) 
(1d) 
 
 
4 
We were particularly interested in the saturation 1 
magnetization value because this is another key indicator in 2 
assessing IONPs sensitivity for biosensing applications 3 
(Colombo et al. 2012). 4 
Magnetization curves were performed on a solid sample. 5 
IONPs 4 showed a paramagnetic behaviour with a saturation 6 
magnetization value of 1.49E-03 emu/g (Figure 2), 7 
confirming also that IONPs 4 present a degree of surface 8 
functionalisation. 9 
 10 
Fig 2. Magnetization curve of IONPs 4 at 310K 11 
 12 
To further demonstrate the potential applicability of 13 
nanoparticles 4 in pre-clinical and clinical fields, we felt 14 
mandatory to perform toxicological screenings. After being 15 
cultured in the presence of nanoparticles 4 at various 16 
concentrations for one to three days, both metabolic activity 17 
(Figure 3) and total DNA of HUVECs (Figure 4) were 18 
performed, with no cytotoxicity or changes in cell viability 19 
and morphology encountered. 20 
 21 
Fig. 3 Metabolic profiles of HUVEC cells treated at different 22 
concentrations of IONPs 4. 23 
 24 
 25 
Fig. 4 Total DNA of HUVEC cells treated at different 26 
concentrations of IONPs 4. 27 
 28 
 29 
 30 
These results strongly suggest that targeted contrast reagents 31 
based on IONPs 4 can be safely used in pre-clinical and 32 
clinical imaging or magnetic-nanomedicine.  33 
The relaxation rate is another key parameter in the 34 
applicability of nanoparticles 4 in preclinical and clinical 35 
fields. We plan to obtain this parameter as a part of our future 36 
applications in vivo, and the results will be reported in due 37 
course. 38 
 39 
Conclusions 40 
 41 
We have developed an operationally simple, high-yielding 42 
and cost-effective protocol to produce a novel class of low 43 
toxicity, tetrazine-based IONPs. Our protocol is reproducible 44 
and the tetrazine motif can be exploited for the preparation of 45 
conjugated biomolecules or drug molecules for targeted-46 
based contrast agents or nanomedicine by using all the 47 
strengths of the well-known copper-free click chemistry. 48 
Targeted magnetic nanoparticle-based contrast agents and 49 
nanomedicines are rapidly emerging into the preclinical and 50 
clinical fields. We therefore anticipate that our method can 51 
represent an invaluable breakthrough and provides a multi-52 
functional nanoparticle platform for the large-scale 53 
production and commercialization of improved, tissue 54 
specific contrast agents or magnetic nanomedicine for the 55 
clinical diagnosis and therapy of diseases at an asymptomatic 56 
stage. 57 
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